Psychiatric disorders are highly prevalent, often devastating diseases that negatively impact
the lives of millions of people worldwide. Although their etiological and diagnostic …

Neurotrophic factors, particularly BDNF (brain-derived neurotrophic factor), have been
associated with depression and antidepressant drug action. A variety of preclinical and …

Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, has revolutionized the
treatment of depression because of its potent, rapid and sustained antidepressant effects …

Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative
anesthetic ketamine induces rapid and sustained antidepressant actions. Although this …

Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

A revamped interest in the study of hallucinogens has recently emerged, especially with
regard to their potential application in the treatment of psychiatric disorders. In the last …

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

How do antidepressants elicit an antidepressant response? Here, we review accumulating
evidence that the neurotrophin brain-derived neurotrophic factor (BDNF) serves as a …

Treating major depression is a medical need that remains unmet by monoaminergic
therapeutic strategies that commonly fail to achieve symptom remission. A breakthrough in …

Depression is a well-known serious mental illness, and the onset of treatment using
traditional antidepressants is frequently delayed by several weeks. Moreover, numerous …